Regulatory Approval, Customer Safety Alert, Patient Support Program Launch, Earnings Releases, and Rating - Research Reports on Medtronic, Covidien, Biogen Idec, Baxter and Express Scripts

NEW YORK, October 21, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Baxter International Inc. (NYSE: BAX) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7332-100free.

--
Medtronic, Inc. Research Reports
On October 14, 2014, Medtronic, Inc. (Medtronic) announced that its CapSureFix Novus(TM) MRI SureScan® 5076 Lead has received U.S. Food and Drug Administration (FDA)'s approval for use with magnetic resonance imaging (MRI). Medtronic informed that with the new FDA approval, two 5076 MRI leads can now be paired with dual-chamber Medtronic Advisa MRI(TM) or Revo MRI(TM) SureScan® pacemakers, allowing patients with these complete SureScan pacing systems to undergo full-body MRI scans. "This is especially important for patients who need MRIs and received 5076 leads at the time of their initial implants; although they may not have received MR-conditional pacemakers initially, they now have the option to get a pacemaker approved for MRI when they require a device change-out, making the entire system MR-conditional," said Brian Urke, Vice President and General Manager of the bradycardia business at Medtronic. The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/MDT/report.pdf

--
Covidien plc Research Reports
On October 10, 2014, Covidien plc (Covidien) announced that it has notified customers of a voluntary Field Safety Alert for certain Medi-Trace™ Cadence and Kendall™ Multi-function Defibrillation Electrodes due to a connector compatibility issue with Philips FR3 and FRx Defibrillators. According to the Company, a total of 644,460 electrodes affected by this safety alert, and these electrodes will not connect with Philips FR3 or FRx AED units, and in the case of the use of Covidien defibrillation electrodes with the Philips FR3 AED units, could result in a delay of therapy. The alert was sent after Covidien received two reports where customers used a Covidien electrode with a Philips FR3 AED unit and faced a delay in resuscitation which, probably, also contributed to the death of one patient. The Company also recommended using Philips FR3 and FRx AED units only with Philips brand electrodes specified in the equipment manual. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/COV/report.pdf

--
Biogen Idec Inc. Research Reports
On October 15, 2014, Biogen Idec Inc. (Biogen Idec) announced the launch of MS Blueprint™ -- a new program that supports people living with multiple sclerosis (MS) by directing their focus on activities that may bring joy to their lives every day. Inspired by happiness expert Gretchen Rubin's approach to creating a more contented life, the new program allows people to set goals, create personalized MS Blueprints, and take small steps toward a more positive life. According to the Company, this chronic disease of the central nervous system affects approximately 400,000 Americans currently. The full research reports on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/BIIB/report.pdf

--
Baxter International Inc. Research Reports
On October 16, 2014, Baxter International Inc. (Baxter) announced better-than-expected Q3 2014 financial results. The Company said that its adjusted net income during the quarter increased to $741 million, or $1.35 per diluted share, from $681 million or $1.24 per diluted share in the year ago period. The net income exceeded Baxter's own previously issued earnings guidance of $1.28 to $1.32 per diluted share. Baxter's net sales during the quarter also rose 13.1% YoY to $4.2 billion. According to Reuters, analysts on average had expected the Company's adjusted earnings at $1.31 per share on revenue of $4.2 billion. Baxter's Medical Products sales rose 17.2% YoY to $2.5 billion, and excluding Gambro revenues from both periods, Medical Products sales grew 4%. Shares of the Company closed at $68.18, down 0.23% from the previous close. The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/BAX/report.pdf

--
Express Scripts Holding Company Research Reports
On October 15, 2014, Express Scripts Holding Company (Express Scripts) announced that its 2015 Express Scripts Medicare® prescription drug plan S5660 (PDP) earned a 4-Star rating from the Centers for Medicare & Medicaid Services (CMS). "Earning a 4-star rating from CMS demonstrates that our plan provides real value to our beneficiaries, and it makes a difference in our members' satisfaction and their overall health outcomes," said Mike Looney, Vice President, Medicare prescription drug plans, Express Scripts. The full research reports on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Oct-21-2014/ESRX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review